CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Proulx, F.
Right arrow Articles by Caroll, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Proulx, F.
Right arrow Articles by Caroll, S.

Clinical and Diagnostic Laboratory Immunology, September 1999, p. 773-773, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

LETTERS TO THE EDITOR

Increased Circulating Levels of Lipopolysaccharide Binding Protein in Children with Escherichia coli O157:H7 Hemorrhagic Colitis and Hemolytic Uremic Syndrome


    LETTER
Top
Letter
References

We report double-determinant sandwich enzyme-linked immunosorbent assay measurements (4) of lipopolysaccharide (LPS) binding protein (LBP) in children with uncomplicated Escherichia coli O157:H7 hemorrhagic colitis (HC) and those with O157:H7-associated hemolytic uremic syndrome (HUS). Characteristics of these children have been previously reported (5). The analytical sensitivity of LBP measurement was 1 ng/ml, and assay precision was 14%. Figure 1 shows that elevated levels of LBP in plasma were noted for children with O157:H7 infections (HC versus normal controls, P < 0.0001) and that concentrations were increased twofold among those who developed HUS (uncomplicated HC versus HUS, P < 0.005). Levels of circulating LPB in HUS were comparable to those preivously noted for patients with inflammatory bowel disease and approximately half those of patients with sepsis (1). In our population, LBP measurements were not correlated to the leukocyte count, interleukin 6 (IL-6), IL-8, or soluble L-, E-, or P-selectin but were significantly correlated with levels of IL-10 (r = 0.6, P < 0.0008), IL-1 receptor antagonist (r = 0.6; P < 0.0005), and soluble intercellular adhesion molecular 1 (ICAM) (R = 0.4; P < 0.02).


View larger version (9K):
[in this window]
[in a new window]
 
FIG. 1.   ---Circulating LBP concentrations in E. coli O157:H7 infections (mean ± 95% confidence intervals [CI]). LBP levels in plasma among 10 normal controls (NC), 15 children with uncomplicated HC, and 10 children with HUS. Subjects were matched for the time interval elapsed between onset of enteritis and blood sample collection (6.5 ± 3.3 versus 6.8 ± 3.8 days, respectively [not a significant difference]). Twofold-increased LBP concentrations were noted for children with HUS compared to those with uncomplicated HC (P < 0.005 [Mann-Whitney U test]). Among 9 children with uncomplicated HC, serial LBP measurements were as follows (means ± 95% CI): first sample, 8.7 ± 6.2 pg'ml; second sample, 4.0 ± 3.4 pg/ml (P <MEASUREME0.01). LBP concentrations remained lower than those among children with HUS (P < 0.009).

LBP is a 60-kDa acute-phase response protein synthesized by hepatocytes which potentiates the LPS-induced stimulation of CD14+ cells such as macrophages and neutrophils; LBP may also activate CD14- epithelial or endothelial cells through the binding with soluble CD14 (6). Secretion of cytokines and adhesion molecules induced by LPS results in neutrophil activation. Interestingly, we detected an association between circulating LBP levels and anti-inflammatory cytokines (IL-10 and IL-1 receptor antagonist) which are classically produced by macrophages (5).

Circulating endotoxin immune complexes have been demonstrated in HUS due to shigellosis only (3). Nevertheless, the involvement of LPS in the pathophysiology of verotoxigenic E. coli infections has been hypothesized (2). Our data indicate that the acute-phase response to LPS is associated with the severity of illness during O157:H7 infections. It remains to be determined if the amount of bacterial inoculum or the effect of renal reabsorption of LBP may account for the increased levels noted during HUS. However, only one child received antibiotic therapy before blood sample collection. Consequently, our data should not have been affected by this parameter. Further studies are needed to determine the role of endotoxin in the pathophysiology of E. coli O157:H7 infections.


    REFERENCES
Top
Letter
References

1. Caroll, S. F., R. L. Dedrick, and M. L. White. 1997. Plasma levels of lipopolysaccharide binding protein correlate with outcome in sepsis and other patients. Shock 8:101.
2. Karpman, D., H. connell, M. Svensson, A. Scheutz, P. Alm, and Svanborg. 1997. The role of lipopolysaccharides and Shiga-like toxin in a model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175:611-620[Medline].
3. Koster, F., J. Levin, L. Walker, K. S. K. Tung, R. H. Gilman, M. M. Rahaman, M. A. Majid, S. Islam, and R. C. Williams. 1979. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N. Engl. J. Med. 298:927-933[Abstract].
4. Meszaros, K., S. Aberle, M. White, and J. B. Parent. 1995. Immunoreactivity and bioactivity of lipopolysaqccharide-binding protein in normal and heat-inactivated sera. Infect. Immun. 63:363-365[Abstract].
5. Proulx, F., C. Litalien, J. P. Turgeon, M. M. Mariscalco, and E. Seidman. 1998. Inflammatory mediators in hemorrhagic colitis and hemolytic uremic syndrome. Pediatr. Inf. dis. J. 17:899-904. [Medline]
6. Write, S. D. 1991. CD14 and immune response to lipopolysaccharide. Science 252:1321-1322[Free Full Text].
François Proulx
Ernest Seidman
Department of Pediatrics
Sainte-Justine Hospital
University of Montreal
Canada
Michelle M. Mariscalco
Department of Pediatrics
Texas Children's Hospital
Baylor College of Medicine
Houston, Texas
Kelly Lee
Stephen Caroll
XOMA Corporation
Berkeley, California


Clinical and Diagnostic Laboratory Immunology, September 1999, p. 773-773, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Proulx, F.
Right arrow Articles by Caroll, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Proulx, F.
Right arrow Articles by Caroll, S.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS